Suppr超能文献

皮脂腺癌:争议及其对临床实践的证据。

Sebaceous carcinoma: controversies and their evidence for clinical practice.

机构信息

Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.

Division of Dermatology, The Ottawa Hospital, Ottawa, ON, Canada.

出版信息

Arch Dermatol Res. 2020 Jan;312(1):25-31. doi: 10.1007/s00403-019-01971-4. Epub 2019 Aug 30.

Abstract

Sebaceous carcinoma (SC) is a potentially aggressive malignancy of periocular or extraocular skin. It arises sporadically or is associated with Muir-Torre syndrome (MTS). Here, we review three controversial clinical conundra related to the diagnosis and treatment of SC and offer evidence-based recommendations. First, following a diagnosis of SC, deciding which patients to screen for MTS can be challenging. The Mayo MTS Risk Score is a clinical score that incorporates the key cutaneous findings in MTS but relies heavily on personal and family history that may not be available at the time of SC diagnosis, especially in young patients. Young patients, who have extraocular SC and are suspected to have MTS though do not meet criteria by Mayo MTS Risk Score, should have their tumors tested using immunohistochemistry for mismatch repair proteins. Second, sentinel lymph node biopsy (SLNB) is used in periocular SC to evaluate nodal disease. Patient selection is critical for SLNB. Periocular SC stage ≥ T2c (by American Joint Commission on Cancer, 8th edition) may be considered for SLNB given positivity rates over fifteen percent in expert hands. Lastly, treatment of metastatic SC is an area of active investigation. When possible, tumor profiling may be used to select targeted agents. Future research into these three key questions is needed.

摘要

皮脂腺癌 (SC) 是一种潜在侵袭性的眼周或眼外皮肤恶性肿瘤。它可以是散发性的,也可以与 Muir-Torre 综合征 (MTS) 相关。在这里,我们回顾了与 SC 的诊断和治疗相关的三个有争议的临床难题,并提供了基于证据的建议。首先,在诊断出 SC 后,决定对哪些患者进行 MTS 筛查可能具有挑战性。Mayo MTS 风险评分是一种临床评分,它包含了 MTS 的关键皮肤表现,但严重依赖于个人和家族史,而这些信息在 SC 诊断时可能并不完整,尤其是在年轻患者中。对于那些有眼外 SC 且疑似患有 MTS 但不符合 Mayo MTS 风险评分标准的年轻患者,应使用免疫组织化学检测错配修复蛋白来检测其肿瘤。其次,前哨淋巴结活检 (SLNB) 用于评估眼周 SC 的淋巴结疾病。患者选择对于 SLNB 至关重要。对于美国癌症联合委员会第 8 版分期≥T2c(periocular SC stage)的患者,在专家手中阳性率超过 15%时,可能考虑进行 SLNB。最后,转移性 SC 的治疗是一个积极研究的领域。在可能的情况下,肿瘤分析可用于选择靶向药物。需要对这三个关键问题进行未来研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验